1. Scrip
  2. >>Business
  3. >>Deals

Myovant Accepts Higher Sumitovant Offer In Deal That Values It At $2.9bn

Women’s Health, Prostate Cancer Assets To Get A Boost

 
• By Mandy Jackson

Sumitovant, a Sumitomo subsidiary, will pay $27 per share for the 48% of Myovant shares it does not already own, for a deal value of $1.7bn, up from a $22.75-per-share bid in early October.

Big fish eats smaller fish
Sumitomo subsidiary Sumitovant is buying the remaining shares of Myovant • Source: Shutterstock

The revised terms of Sumitovant Biopharma Ltd.’s bid to purchase the portion of outstanding Myovant Sciences Ltd. shares that it does not own brings revenue-generating products fully into parent company Sumitomo Pharma Co., Ltd.’s portfolio at a critical time. And in addition to generating a better return for Myovant’s minority shareholders, the deal, announced on 24 October, increases the resources behind the smaller firm’s women’s health and prostate cancer drug portfolio.

Sumitovant, a wholly owned Sumitomo subsidiary, already owns 52% of Myovant’s shares but it now has agreed to pay $27 each for the remaining shares, or $1.7bn. The all-cash deal values Myovant at $2.9bn, compared with the $2.4bn enterprise value of Sumitovant’s offer three weeks ago of $22.75 per share, which Myovant’s board of directors had rejected as not reflecting the true value of the commercial-stage company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.